Gilead cir­cles Feb­ru­ary 12 on its cal­en­dar as D-day for its HIV fran­chise

It won’t be long now be­fore Gilead gets an of­fi­cial an­swer on its mar­ket­ing ap­pli­ca­tion for a new HIV triple with megablock­buster po­ten­tial.

The FDA has put this ap­pli­ca­tion on the pri­or­i­ty re­view track for its com­bi­na­tion of bicte­gravir with its back­bone HIV drugs emtric­itabine/teno­fovir alafe­namide (200/25mg) (FTC/TAF) — Gilead had filed this ap­pli­ca­tion with a pri­or­i­ty re­view vouch­er — af­ter the treat­ment post­ed im­pres­sive ef­fi­ca­cy re­sults.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.